Women's Cancer News
Jan. 28, 2015

Veliparib trial fails to improve outcomes in ovarian cancer
Cancer Network
Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. However, the study published in Clinical Cancer Research did demonstrate that oral cyclophosphamide was well-tolerated among this patient population and was associated with responses and prolonged disease stabilization.More

SGO Board of Directors and Foundation Council open election

The 2015 SGO Board of Directors and Foundation Council open election is now under way. All SGO members who are eligible to vote should have received an email from noreply@directvote.net on Monday, Jan. 12. The list of candidates for each position, including biographical information, personal statements and photos, is available for your consideration. Please take some time to review the candidates’ statements prior to casting your vote. Candidate information is also available on the ballot. Voting ends at 11:59 p.m. CST on Friday, Feb. 13. More

Researchers pinpoint two genes that trigger severest form of ovarian cancer
Medical Xpress
In the battle against ovarian cancer, UNC School of Medicine researchers have created the first mouse model of the worst form of the disease and found a potential route to better treatments and much-needed diagnostic screens. "It's an extremely aggressive model of the disease, which is how this form of ovarian cancer presents in women," said Terry Magnuson, PhD, who is also a member of the UNC Lineberger Comprehensive Cancer Center. Not all mouse models of human diseases provide accurate depictions of the human condition. Magnuson's mouse model, though, is based on genetic mutations found in human cancer samples. The study was published recently in Nature Communications.More

RNA test for HPV helps stratify cervical cancer risk
Cancer Network
A test for several dangerous strains of high-risk human papillomavirus (HPV) using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification among women with atypical results of a Papanicolaou (Pap) test, according to the results of a new study. Results from the CLEAR study previously led to U.S. Food and Drug Administration of approval of genotype assay in October 2012. This new analysis reflex tested women with a positive test using a specific HPV 16 18/45 genotype assay (AHPV-GT) for further stratification.More

HPV vaccine often not received at recommended age
HealthDay News via MPR
Only about half of American girls begin receiving the human papillomavirus (HPV) vaccine at the recommended age, according to a study to be published in the Jan. 29 issue of Vaccine. Girls should begin getting the three-dose HPV vaccine when they are 11 or 12. The vaccine is most effective before girls become sexually active, according to the U.S. Centers for Disease Control and Prevention. The CDC also recommends the vaccine for boys beginning at ages 11 or 12. However, the current study only looked at girls.More

Oestrogen receptor ligands show promise for treating endometriosis
The Pharmaceutical Journal
Researchers studying endometriosis have discovered a potential way to treat the disease that avoids many of the side effects seen with existing therapies. Two compounds, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which both bind to oestrogen receptors, were shown to control inflammation and reduce lesions in mice models without affecting fertility. The researchers, led by a team at the University of Illinois at Urbana-Champaign in the United States, say their work, published in Science Translational Medicine, has also provided greater insight into the causes and progression of the disease.More

Portable cervical cancer treatment may help women in remote areas receive care they need
Medical Daily
At one point cervical cancer was the most common cause of death for women in America under the age of 30. Today, thanks to increased use of the Pap smear test, the death rate from this form of cancer has gone down by 50 percent, The American Cancer Society reports. Unfortunately, this is not the case in many remote villages in developing countries. Here many women still do not get life-saving screenings for the cancer due to shame or simply not understanding the importance. A team of Peruvian doctors are working to change that. They hope to revamp an old dermatological device into a portable cervical cancer treatment which will be able to get the necessary help to the women who need it, no matter where they live.More

Breast cancer patients lack knowledge of their tumors
Women with breast cancer often don’t know what kind of tumors they have, a new study published in Cancer found. Not knowing one’s tumor features isn’t necessarily tied to worse outcomes, but better knowledge might help women understand treatment decisions and take medications as directed, said Dr. Rachel Freedman, the study’s lead author from the Dana-Farber Cancer Institute in Boston. Also, she said, cancer patients who understand the basis for their treatment are generally more satisfied with that treatment.More

'Historic' timeline set for basing Medicare pay on 'value'
Medscape (Free login required)
The Obama administration wants half of all Medicare payments to physicians and hospitals in 2018 to be made through alternative payment models such as medical homes and accountable care organizations (ACOs) as part of a "historic" timetable for basing reimbursement on value, not volume, the government announced today. In addition, the Department of Health and Human Services (HHS) has set a goal of tying 85 percent of all fee-for-service (FFS) payments to quality and cost measures by 2016, and 90 percent by 2018.More